Ocugen pays U.S.D. 15 million upfront to Bharat Biotech for Covaxin rights in Canada
Bharat Biotech on June 3 said it has agreed to expand the agreement with Ocugen Inc to commercialize the jab in Canada also
Ocugen pays U.S.D. 15 million upfront to Bharat Biotech for Covaxin rights in Canada
Ocugen Inc, the U.S. partner for Bharat Biotech COVID-19 vaccine, had announced payment of U.S.D. 15 million upfront to the Indian drug maker for extending the vaccine rights to Canada. Ocugen in a regulatory filing said it has agreed to pay another USD 10 million to Bharat Biotech within a month from the commercial launch of Covaxin in the North American country.
Bharat Biotech on June 3 said it has agreed to expand the agreement with Ocugen Inc to commercialize the jab in Canada also. The Amendment is effective as of May 29, 2021. In consideration of the expansion, pursuant to the Amendment, the Company paid to Bharat (Bharat Biotech) a non-refundable, upfront payment of USD 15 million immediately upon execution of the Amendment. The company further agreed to pay to Bharat a milestone payment of USD 10 million within 30 days of the first commercial sale of Covaxin in Canada.
According to Shankar Musunuri, Co-founder of Ocugen, the company which is working towards the submission of the emergency use application in the US, will simultaneously seek authorization under interim order for emergency use in Canada.
